SEARCH

SEARCH BY CITATION

References

  • 1
    Charlton M. Natural history of hepatitis C and outcomes following liver transplantation. Clin Liver Dis 2003; 7: 585602.
  • 2
    Neuberger J. Incidence, timing, and risk factors for acute and chronic rejection. Liver Transpl Surg 1999; 5: S30S36.
  • 3
    Knechtle SJ. Rejection of the liver transplant. Semin Gastrointest Dis 1998; 9: 126135.
  • 4
    Neumann UP, Berg T, Bahra M et al. Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up. Transplantation 2004; 77: 226231.
  • 5
    Berenguer M, Lopez-Labrador FX, Greenberg HB, Wright TL. Hepatitis C virus and the host: an imbalance induced by immunosuppression? Hepatology 2000; 32: 433435.
  • 6
    Berenguer M. Natural history of recurrent hepatitis C. Liver Transpl 2002; 8: S14S18.
  • 7
    Regev A, Molina E, Moura R et al. Reliability of histopathologic assessment for the differentiation of recurrent hepatitis C from acute rejection after liver transplantation. Liver Transpl 2004; 10: 12331239.
  • 8
    Lake JR. The role of immunosuppression in recurrence of hepatitis C. Liver Transpl 2003; 9: S63S66.
  • 9
    Tannapfel A, Wittekind C. Differential diagnosis of acute rejection versus hepatitis reinfection. Transplant Proc 2003; 35: 20822083.
  • 10
    Berenguer M. Host and donor risk factors before and after liver transplantation that impact HCV recurrence. Liver Transpl 2003; 9: S44S47.
  • 11
    Wietzke-Braun P, Braun F, Sattler B, Ramadori G, Ringe B. Initial steroid-free immunosuppression after liver transplantation in recipients with hepatitis C virus related cirrhosis. World J Gastroenterol 2004; 10: 22132217.
  • 12
    Berenguer M, Crippin J, Gish R et al. A model to predict severe HCV-related disease following liver transplantation. Hepatology 2003; 38: 3441.
  • 13
    Michaels PJ, Fishbein MC, Colvin RB. Humoral rejection of human organ transplants. Springer Semin Immunopathol 2003; 25: 119140.
  • 14
    Regele H, Bohmig GA, Habicht A et al. Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: a contribution of humoral immunity to chronic allograft rejection. J Am Soc Nephrol 2002; 13: 23712380.
  • 15
    Crespo M, Pascual M, Tolkoff-Rubin N et al. Acute humoral rejection in renal allograft recipients: I. Incidence, serology and clinical characteristics. Transplantation 2001; 71: 652658.
  • 16
    Mauiyyedi S, Colvin RB. Humoral rejection in kidney transplantation: new concepts in diagnosis and treatment. Curr Opin Nephrol Hypertens 2002; 11: 609618.
  • 17
    Haga H, Egawa H, Shirase T et al. Periportal edema and necrosis as diagnostic histological features of early humoral rejection in ABO-incompatible liver transplantation. Liver Transpl 2004; 10: 1627.
  • 18
    Banff schema for grading liver allograft rejection: an international consensus document. Hepatology. 1997; 25: 658663. Review.
  • 19
    Demetris A, Adams D, Bellamy C et al. Update of the international Banff schema for liver allograft rejection: working recommendations for the histopathologic staging and reporting of chronic rejection. An International Panel. Hepatology 2000; 31: 792799.
  • 20
    Dankof A, Schmeding M, Morawietz L et al. Portal capillary C4d deposits and increased infiltration by macrophages indicate humorally mediated mechanisms in acute cellular liver allograft rejection. Virchows Arch 2005; 447: 8793.
  • 21
    Krukemeyer MG, Moeller J, Morawietz L et al. Description of B lymphocytes and plasma cells, complement, and chemokines/receptors in acute liver allograft rejection. Transplantation 2004; 78: 6570.
  • 22
    Moeller J, Krukemeyer MG, Morawietz L et al. Molecular case report: IgVH analysis in acute humoral and cellular liver allograft rejection suggests a selected accumulation of effector B cells and plasma cells. Virchows Arch 2005; 446: 325332.
  • 23
    Crespo M, Lozano M, Sole M, et al. Diagnosis and treatment of acute humoral rejection after kidney transplantation: preliminary experience. Transplant Proc 2003; 35: 16771678.
  • 24
    Magil AB, Tinckam K. Monocytes and peritubular capillary C4d deposition in acute renal allograft rejection. Kidney Int 2003; 63: 18881893.
  • 25
    Feucht HE, Schneeberger H, Hillebrand G et al. Capillary deposition of C4d complement fragment and early renal graft loss. Kidney Int 1993; 43: 13331338.
  • 26
    Feucht HE, Felber E, Gokel MJ et al. Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection. Clin Exp Immunol 1991; 86: 464470.
  • 27
    Mauiyyedi S, Pelle PD, Saidman S et al. Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. J Am Soc Nephrol 2001; 12: 574582.
  • 28
    Nickeleit V, Zeiler M, Gudat F, Thiel G, Mihatsch MJ. Detection of the complement degradation product C4d in renal allografts: diagnostic and therapeutic implications. J Am Soc Nephrol 2002; 13: 242251.
  • 29
    Nickeleit V, Mihatsch MJ. Kidney transplants, antibodies and rejection: is C4d a magic marker? Nephrol Dial Transplant 2003; 18: 22322239.
  • 30
    Lorenz M, Regele H, Schillinger M et al. Risk factors for capillary C4d deposition in kidney allografts: evaluation of a large study cohort. Transplantation 2004; 78: 447452.
  • 31
    Sawada T, Shimizu A, Kubota K, Fuchinoue S, Teraoka S. Lobular damage caused by cellular and humoral immunity in liver allograft rejection. Clin Transplant 2005; 19: 110114.
  • 32
    Sebagh M, Blakolmer K, Falissard B et al. Accuracy of bile duct changes for the diagnosis of chronic liver allograft rejection: reliability of the 1999 Banff schema. Hepatology 2002; 35: 117125.
  • 33
    Ormonde DG, De Boer WB, Kierath A et al. Banff schema for grading liver allograft rejection: utility in clinical practice. Liver Transpl Surg 1999; 5: 261268.
  • 34
    Demetris AJ, Eghtesad B, Marcos A et al. Recurrent hepatitis C in liver allografts: prospective assessment of diagnostic accuracy, identification of pitfalls, and observations about pathogenesis. Am J Surg Pathol 2004; 28: 658669.
  • 35
    Prieto M, Berenguer M, Rayon JM et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology 1999; 29: 250256.
  • 36
    Sreekumar R, Rasmussen DL, Wiesner RH, Charlton MR. Differential allograft gene expression in acute cellular rejection and recurrence of hepatitis C after liver transplantation. Liver Transpl 2002; 8: 814821.
  • 37
    Ciccorossi P, Filipponi F, Oliveri F et al. Usefulness of IgM anti-HCV in differential diagnosis between recurrent hepatitis C and acute rejection in liver transplant patients. Transplant Proc 2001; 33: 36413642.
  • 38
    Ciccorossi P, Filipponi F, Oliveri F et al. Increasing serum levels of IgM anti-HCV are diagnostic of recurrent hepatitis C in liver transplant patients with ALT flares. J Viral Hepat 2003; 10: 168173.
  • 39
    Gottschlich MJ, Aardema KL, Burd EM et al. The use of hepatitis C viral RNA levels in liver tissue to distinguish rejection from recurrent hepatitis C. Liver Transpl 2001; 7: 436441.
  • 40
    Baid S, Tolkoff-Rubin N, Saidman S et al. Acute humoral rejection in hepatitis C-infected renal transplant recipients receiving antiviral therapy. Am J Transplant 2003; 3: 7478.
  • 41
    Baid S, Cosimi AB, Tolkoff-Rubin N, Colvin RB, Williams WW, Pascual M. Renal disease associated with hepatitis C infection after kidney and liver transplantation. Transplantation 2000; 70: 255261.
  • 42
    Samuel D. Hepatitis C, interferon, and risk of rejection after liver transplantation. Liver Transpl 2004; 10: 868871.
  • 43
    Stravitz RT, Shiffman ML, Sanyal AJ et al. Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation. Liver Transpl 2004; 10: 850858.
  • 44
    Jain A, Demetris AJ, Manez R et al. Incidence and severity of acute allograft rejection in liver transplant recipients treated with alfa interferon. Liver Transpl Surg 1998; 4: 197203.